Back Back
Cell No. : Cell Name
RCB0487 : CHP-134  update : 2024/03/08
CommentHuman cell line derived from Neuroblastoma. N-myc gene is amplified. Application consideration
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Nishi, Yoshisuke
Originator Schlesinger, H. R.
Year of deposit 1990
Animal _human < Mammals
Genus Homo
Species sapiens
Gender Male
Age at sampling 13 months
Tissue adrenal, left
Disease name neuroblastoma (stage IV)
Classification cancer
History Latt, S. A.
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_1124
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin (1min.) or pipetting
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : 1-2 times/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) (-)
Isozyme LD, NP, AST, MPI
Chromosome mode 44-47(50) : 44(1),45(6),46(41),47(2)
STR(human) OK
deposit info
lot info
Reference information Reference 5
User's Publication 9

To topTop
1287  Gilbert F, Feder M, Balaban G, Brangman D, Lurie, D K, Podolsky R, Rinaldt V, Vinikoor N, Weisband J  Human neuroblastomas and abnormalities of chromosomes 1 and 17.  Cancer Res  1984  44:5444-9  PubMed ID: 6488196  
246  Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J.  Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour  Nature  1983  305(5931):245-8  PubMed ID: 6888561   DOI: 10.1038/305245a0
1286  U V Santer, M C Glick  Presence of fucosyl residues on the oligosaccharide antennae of membrane glycopeptides of human neuroblastoma cells  Cancer Res  1983  43(9):4159-66  PubMed ID: 6871857  
1127  Gilbert F, Balaban G, Moorhead P, Bianchi D, Schlesinger H  Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines.  Cancer Genet Cytogenet  1982  7:33-42  PubMed ID: 7139592   DOI: 10.1016/0165-4608(82)90105-4
1215  Schlesinger, H R, Gerson, J M, Moorhead, P S, Maguire H, Hummeler K  Establishment and characterization of human neuroblastoma cell lines.  Cancer Res  1976  36:3094-100  PubMed ID: 10079  

To topTop
User's Publication
19684  Ando K, Suenaga Y, Kamijo T.  DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in MYCN-Amplified Neuroblastoma IMR32 Cells  Int J Mol Sci  2023  24(10):9012  PubMed ID: 37240360   DOI: 10.3390/ijms24109012
21471  Hasan MN, Hyodo T, Biswas M, Rahman ML, Mihara Y, Karnan S, Ota A, Tsuzuki S, Hosokawa Y, Konishi H.  Flow cytometry-based quantification of genome editing efficiency in human cell lines using the L1CAM gene.  PLoS One  2023  18(11):e0294146  PubMed ID: 37943774   DOI: 10.1371/journal.pone.0294146
20297  Liu C, Gen Y, Tanimoto K, Muramatsu T, Inoue J, Inazawa J.  Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells.  Mol Ther Nucleic Acids  2021  25:83-92  PubMed ID: 34258104   DOI: 10.1016/j.omtn.2021.05.001
20445  Komata Y, Tsubota S, Sakamoto K, Ikematsu S, Kadomatsu K.  Screening of novel Midkine binding protein by BioID2-based proximity labeling.  Nagoya J Med Sci  2021  83(3):495-508  PubMed ID: 34552285   DOI: 10.18999/nagjms.83.3.495
13221  Ando K, Cázares-Ordoñez V, Makishima M, Yokoyama A, Suenaga Y, Nagase H, Kobayashi S, Kamijo T, Koshinaga T, Wada S.  CEP131 Abrogates CHK1 Inhibitor-Induced Replication Defects and Is Associated with Unfavorable Outcome in Neuroblastoma.  J Oncol  2020    PubMed ID: 33014050   DOI: 10.1155/2020/2752417
15663  Tanimoto T, Tazawa H, Ieda T, Nouso H, Tani M, Oyama T, Urata Y, Kagawa S, Noda T, Fujiwara T.  Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression  Mol Ther Oncolytics  2020  18:14-2  PubMed ID: 32637577   DOI: 10.1016/j.omto.2020.05.015
14883  Ando K, Nakamura Y, Nagase H, Nakagawara A, Koshinaga T, Wada S, Makishima M.  Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells  Int J Mol Sci  2019  20(15):3700  PubMed ID: 31362335   DOI: 10.3390/ijms20153700
14739  Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J.  Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor  J Natl Cancer Inst  2017  109(11)  PubMed ID: 29059438   DOI: 10.1093/jnci/djx062
2916  Abe, Masanobu, Ohira, Miki, Kaneda, Atsushi, Yagi, Yukiko, Yamamoto, Seiichiro, Kitano, Yoshihiro, Takato, Tsuyoshi, Nakagawara, Akira, Ushijima, Toshikazu  CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas.  Cancer Res  2005  65:828-34  PubMed ID: 15705880  

Back Back Return Top Page